Annovis Bio (ANVS) Q2 2024 earnings summary

Executive summary

• Completed pivotal Phase 2/3 Alzheimer's and Phase 3 Parkinson's studies, both showing encouraging data for buntanetap, with topline data released in 2024.

• Buntanetap showed statistically significant improvements in cognition for early AD and motor function for PD in subgroups, with further FDA discussions planned for late 2024.

• Introduced a new crystalline form of buntanetap with improved properties, strengthening the IP portfolio.

• Expanded leadership team with key appointments in business, communications, statistics, and quality.

• The company has not generated product revenue and continues to incur operating losses, relying on equity financings for funding.

Financial highlights

• Net loss for Q2 2024 was $5.0 million, improved from $9.5 million in Q2 2023; net loss for the six months ended June 30, 2024 was $6.1 million, down from $19.3 million year-over-year.

• Operating expenses for Q2 2024 were $7.8 million, down 20% year-over-year from $9.8 million.

• Cash and cash equivalents as of June 30, 2024 were $4.0 million, rising to $12.1 million as of August 14, 2024 after recent financings.

• Cash used in operating activities for the first half of 2024 was $10.4 million, down from $21.2 million in the prior year period.

• Net loss per share for Q2 2024 was $(0.44), improved by 59% from $(1.07) in Q2 2023.

Outlook and guidance

• Cash reserves, including recent warrant exercise proceeds and ELOC share sales, are expected to support operations through planned FDA meetings and initiation of pivotal studies in late 2024.

• Substantial additional capital will be required to complete development and commercialization; management is actively seeking further equity or debt financing.

• If unable to raise sufficient capital, the company may need to reduce the scope of operations.

• Forward-looking statements highlight risks related to clinical trial outcomes, patient enrollment, and regulatory timing.